Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
The currently available diphtheria-tetanus-whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-ce...
保存先:
| 出版年: | Infect Immun |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
1994
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC186128/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7507893/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.62.2.449-456.1994 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|